It is with great pleasure that we announce several senior-level promotions and welcome 10 new affiliates to the firm.
Our recently promoted consultants are talented individuals who have shown great creativity and commitment in their work on behalf of our clients. The list of their contributions is long, including analyzing complex financial matters, designing surveys to assess the nuances of consumer behavior, and developing clinical and real-world evidence for novel treatments of serious diseases. We are also pleased to share news of the promotion of an integral operations team member who, among other contributions, has diligently managed the ongoing impact of the pandemic on our firm by enabling a largely remote workforce.
In addition, we are excited to announce our affiliation with 10 renowned academic and industry experts, who are widely recognized leaders in fields such as consumer behavior, taxation, finance, health care, corporate governance, and technology.
Please join me in celebrating the many achievements of our colleagues and in welcoming these new affiliates.
From our ceo
Professor of Marketing and Wolfe Family Presidential Endowed Chair in Life Sciences Innovation and Entrepreneurship, Rady School of Management at UC San Diego
Richard B. Worley Professor of Financial Management and Professor of Accounting, The Wharton School of the University of Pennsylvania
Henry and Allison McCance Professor of Business Administration, Harvard Business School; Ethel Zimmerman Wiener Professor of Public Policy and Director of Health Policy Research, Harvard Kennedy School
Senior Lecturer, MIT Sloan School of Management
Professor of Health Care Policy, Harvard Medical School
CEO, The Governance Partners, LLC
Associate Vice Chancellor, Professor of Biochemistry and Molecular Biophysics, and Director of the Centers for Research Innovation in Biotechnology and Drug Discovery, Washington University in St. Louis
Provost and Professor of Software Engineering, Schaffhausen Institute of Technology; Professor Emeritus of Software Engineering, ETH Zürich (Swiss Federal Institute of Technology); Co-founder, Eiffel Software (Santa Barbara, California)
Executive Director and Research Scientist, Cybersecurity at MIT Sloan, MIT Sloan School of Management
Professor of Finance and Maguire Chair in Energy Management, SMU Cox School of Business
Professor Amir is an expert on consumer behavior – specifically, decision-making mechanisms and their influences on online and offline marketplaces, pricing and promotion strategies, and consumer preferences. His research has also addressed judgment, behavioral economics, risk and uncertainty, and the psychology of money. Professor Amir has been retained as an expert witness and testified at deposition in numerous cases, including consumer protection, trademark, and false advertising/packaging matters. He has also consulted to and conducted market research for companies in the life sciences, biotechnology, media, gaming, and defense industries. Professor Amir’s research has been published in the Journal of Consumer Research, the Journal of Marketing Research, Marketing Science, and Marketing Letters. He frequently speaks on these subjects at conferences and invited talks. Professor Amir has received research grants from the Marketing Science Institute and the Robert Wood Johnson Foundation for his work on consumer choice and reasoning. Prior to joining the Rady School of Management, he was on the faculty of the Yale School of Management.
Professor Blouin is an expert on the role of taxation in firm decision making. Her research examines the effect of taxes on asset pricing, capital structure, corporate payout behavior, multinational firm behavior, and mergers and acquisitions. She has also examined the effects of investor tax-sensitivity on portfolio rebalancing, price pressure, and fund performance. Professor Blouin has provided expert analysis and testimony in tax shelter litigation on behalf of the US Department of Justice, and in pharmaceutical patent litigation regarding transfer pricing and the repatriation of earnings by multinational corporations and their affiliates. Her research has been published in peer-reviewed journals that include the Journal of Accounting and Economics and the National Tax Journal, and she is an editor of the Review of Accounting Studies and an associate editor of the Journal of Accounting Research. Professor Blouin’s work has been cited in The Wall Street Journal, The New York Times, and the Financial Times, as well as on NPR. She is a recipient of the University of Pennsylvania’s Lindback Award for Distinguished Teaching and Wharton Teaching Excellence Award. Prior to her academic career, Professor Blouin was a tax manager with Arthur Andersen.
Professor Chandra focuses his research on innovation, productivity, and cost growth in health care; medical malpractice; and racial disparities in medical care. He has testified before the US Senate and the US Commission on Civil Rights; consulted to the RAND Corporation, Microsoft Research, the National Academy of Medicine, and the Blue Cross Blue Shield of Massachusetts Foundation; and served as a special commissioner on the Massachusetts Special Commission on Provider Price Reform. Professor Chandra is a member of the Congressional Budget Office’s panel of health advisors and an elected member of the National Academy of Medicine and the National Academy of Social Insurance. His research has been published in journals such as the American Economic Review, the Journal of Political Economy, The New England Journal of Medicine, JAMA, and Health Affairs. Professor Chandra has received several awards for his work, including the Kenneth J. Arrow Award for best paper in health economics, the Garfield Award for outstanding research on the economic impact of medical and health research, the National Institute for Health Care Management Foundation Health Care Research Award, and the American Society of Health Economists’ ASHEcon Medal. He is a research associate at the National Bureau of Economic Research.
Professor Gosline’s research focuses on the convergence of behavioral science and technology, and the impact of technology on cognitive bias in human decision making. Her research has employed various experimental methods to examine questions such as when and why humans prefer algorithmic to human input; how consumers decide whether a product is “real” versus “fake”; and the circumstances under which consumers perceive value in platforms. Professor Gosline has consulted to companies on issues such as brand strategy, brand imitation and counterfeits, and the intersection of artificial intelligence and human choice. She has presented conference keynotes, given a TEDx talk, and been featured in numerous media outlets, including The Economist, Forbes, Fortune, and The New York Times. In addition to her position at MIT Sloan, Professor Gosline is a principal research scientist with the MIT Initiative on the Digital Economy and a fellow at Stanford University’s Digital Economy Lab. She serves on ideas42’s scientific advisory board, MIT’s Global Initiatives Committee, and the National Kidney Foundation’s advisory board. Earlier in her career, she held marketing positions at consumer products and advertising companies.
Professor Grabowski specializes in health care economics, with a particular focus on insurance coverage for patients in long-term care, post-acute care, and nursing home settings. He has testified before Congress on payment and quality issues in health care, and was the principal investigator on several research projects funded by the National Institute on Aging. As a member of the Medicare Payment Advisory Commission, Professor Grabowski advises Congress on issues impacting the Medicare program. He has served as a technical expert for numerous organizations, including the Department of Health and Human Services, the US Centers for Medicare & Medicaid Services, and the National Institute on Disability and Rehabilitation Research. His research has been widely published in peer-reviewed journals as well as medical and mainstream media, and has earned support from such organizations as the Robert Wood Johnson Foundation, the Commonwealth Fund, and the Donaghue Foundation. Professor Grabowski is a frequent speaker at national and international health economics conferences.
Ms. Kamerick is an expert in corporate governance, corporate finance, securities law, and mergers and acquisitions (M&A). She has held CFO positions at a number of prominent firms – including BP Amoco (Americas), Heidrick & Struggles, and Houlihan Lokey – and served as a senior financial and legal advisor to major multinational corporations. Ms. Kamerick is a former M&A and securities attorney with Skadden, Arps, Slate, Meagher & Flom. She has significant experience overseeing 401(k) and defined-benefit retirement plans, and chairing defined-benefit retirement plan investment committees. In addition to consulting on financial, strategic, and corporate governance matters, Ms. Kamerick serves on several boards, frequently acting as chair of the audit committee and as the board’s Securities and Exchange Commission financial expert. She also serves on the boards of the Legg Mason Closed-End Mutual Funds and the AIG Funds & Anchor Series Trust (a mutual fund complex). Ms. Kamerick is a National Association of Corporate Directors (NACD) Board Leadership Fellow and holds the NACD Directorship certification. She has held several adjunct professorships and lectured on corporate governance and fiduciary duties at numerous universities, as well as in NACD’s Battlefield to Boardroom program for flag officers. Ms. Kamerick is a frequent contributor to Agenda and Directors & Boards. She serves on the Alzheimer’s Association board of directors, as well as its audit and finance committees. In 2020, she was a judge for IR Magazine’s Corporate Governance Awards.
Professor Kinch, a drug development expert specializing in cancer, immunological, and infectious diseases, focuses on combining cutting-edge science and entrepreneurship to improve public health. At Washington University in St. Louis, Professor Kinch founded and directs the Center for Research Innovation in Biotechnology, which assesses trends that guide the research and development of novel medicines. He also helped create the Center for Drug Discovery to identify and underwrite the university’s most promising drug discovery projects. Professor Kinch has been issued more than a dozen US patents, published more than 100 patent applications, and written several books and book chapters on the commercialization of biopharmaceutical innovation, as well as other aspects of drug development. He has published widely in peer-reviewed journals, including Drug Discovery Today, Science, Cell Chemical Biology, and the Biotechnology Law Report, and his research has been profiled in media outlets such as The Wall Street Journal, NPR, CBS News, and The New York Times. Before joining Washington University, he was the managing director of the Yale Center for Molecular Discovery. He has also taught at Johns Hopkins University and Purdue University, and held senior research positions at Functional Genetics and MedImmune. Professor Kinch serves on the board of the American Cancer Society and on scientific advisory boards for several biopharmaceutical companies.
Professor Meyer specializes in software engineering and the construction of complex reliable systems. His research interests run from the technical (such as software verification, programming languages, and concurrent programming) to the managerial (including large project organizations, agile methods, quality assurance, and troubled-project rescue). Professor Meyer has served as an expert witness in technology-related cases before the US International Trade Commission (ITC), the European Commission (EC), and the International Chamber of Commerce. These include a patent litigation case between Nokia and Apple before the ITC, and a Microsoft antitrust case before the EC. He has consulted to companies in the US, Japan, and Europe. A pioneer of object technology – a now-dominant approach to software design and programming – Professor Meyer designed the Eiffel programming language and established the “design by contract” programming concept. Professor Meyer has published over 300 articles and 12 books, many widely translated, on software issues and techniques. His awards include the IEEE Computer Society’s Harlan D. Mills Award and the Association for Computing Machinery (ACM) Software System Award; he is a member of Academia Europaea, and a fellow of the International Federation for Information Processing as well as the ACM. After co-founding Eiffel Software, he was a professor of software engineering and chairman of the Department of Computer Science at ETH Zürich. In addition to his current role at the Schaffhausen Institute of Technology in Switzerland, Professor Meyer holds associated positions with Politecnico di Milano, the University of Toulouse, and Russia’s Innopolis University. He speaks English, French, Russian, German, and Italian.
Dr. Pearlson is an expert in cybersecurity whose research spans management information systems, business strategy, and organizational design, as well as the development of a culture of cybersecurity to support the mitigation of cyber breaches. She has provided expert witness testimony on information management topics such as data management, information systems leadership responsibilities, reengineering of business process design, and reasonable information protection practices. She has consulted to chief executives at established companies and startups on information technology (IT) strategy, and has led IT leadership development programs. Dr. Pearlson is a founder and managing partner of KP Partners, an advisory and executive education firm for chief information officers (CIOs), chief analytics officers (CAOs), and chief information security officers (CISOs). She is also founder and executive director of the Executive Networks IT Leaders Forum, and the founding director of the Analytics Leadership Consortium at the International Institute of Analytics. Dr. Pearlson is coauthor of Managing and Using Information Systems: A Strategic Approach and Zero Time: Providing Instant Customer Value – Every Time, All the Time! She is a frequent guest speaker and has held positions in academia and industry, including at Babson College, The University of Texas at Austin, the Gartner Research Board, CSC Index, and AT&T.
Professor Venkataraman specializes in market microstructure and financial market design; the evaluation of trading strategies; and the functioning of equity, fixed-income, and energy markets. He has served as an expert witness in litigation matters involving trading strategies and price manipulation, and has consulted to the Financial Industry Regulatory Authority, the US Commodity Futures Trading Commission, and the US Department of Justice, among other organizations. He serves on the US Securities and Exchange Commission’s (SEC’s) Fixed Income Market Structure Advisory Committee, which advises the SEC on the efficiency and resiliency of fixed-income markets. Professor Venkataraman is an associate editor of the Journal of Financial and Quantitative Analysis and the Journal of Financial Markets. His research has been published in academic journals and featured in media outlets such as The Wall Street Journal, Barron’s, the Financial Times, The Economist, and Bloomberg News, and has won best paper awards at international conferences. Professor Venkataraman teaches courses in investments and energy finance, and serves as the academic director of the Maguire Energy Institute. He has served as chairman of the Cox School of Business’s finance department. Professor Venkataraman is the recipient of multiple SMU awards, including the Altshuler Distinguished Teaching Professor Award and the Gerald J. Ford Senior Research Fellowship, and was named among “The Best 40 B-School Profs Under the Age of 40” by Poets&Quants.
Dr. Cliff is a financial economist with expertise in a range of topics, including asset valuation, mergers and acquisitions, tax shelters, stock analysts’ recommendations, IPOs, real estate investment trusts, derivatives, and hedge funds. He has extensive experience with large financial datasets, sophisticated econometric models, and simulations. In his consulting engagements, Dr. Cliff has addressed damages modeling, class certification, business and asset valuation, analysis of complex financial structures, analysis of solvency and debt covenants, evaluation of investment strategies, and assessment of due diligence practices. In these assignments, he has managed large case teams, designed and performed analyses supporting export reports, critiqued opposing expert reports, and assisted with preparation for depositions and trial. Dr. Cliff has also served as an expert on cases involving valuation, damages, and liquidity discounts. Prior to joining Analysis Group, Dr. Cliff was a finance professor for nine years at Purdue University and Virginia Tech, where he taught a variety of courses at the undergraduate, M.B.A., and Ph.D. levels. His academic research has been published in leading journals such as the Journal of Finance, the Journal of Business, and Financial Management.
Mr. Fink specializes in the application of economic analyses to complex business litigation matters. He has provided expert support in a broad range of cases, including antitrust matters, intellectual property (IP) cases, general business litigation, and regulatory proceedings. Mr. Fink has experience supporting experts across a variety of industries, including pharmaceuticals, high tech, agriculture, and media and entertainment. His case work has included antitrust claims against brand and generic drug manufacturers involving allegations of reverse-payment settlements, IP disputes involving biologic and biosimilar pharmaceutical manufacturers, and restraint of trade allegations involving exclusive licensing in the cosmetics industry. He has assisted attorneys, academic affiliates, and industry experts in all phases of complex litigation, including pretrial discovery, case strategy, expert reports, deposition support, and trial preparation.
Ms. Guérin is an economist who specializes in the application of statistics and econometrics to health economics and outcomes research (HEOR) and epidemiology. Her areas of expertise include retrospective database analyses such as medical claims, electronic health records, and clinical trial data; economic modeling, such as cost-effectiveness and budget impact models; and design of chart review studies, surveys, and other prospective studies. She has participated in the development of large clinical data registries and in the design of real-world evidence (RWE) studies to support regulatory submissions. Ms. Guérin has broad research and analytical experience in areas such as comparative effectiveness and cost effectiveness, development of prediction algorithms, assessment of disease prevalence and incidence, evaluation of burden of illness, productivity loss, treatment patterns, analysis of patient-reported outcomes, safety/tolerability analyses, discrete choice experiments, and patient experience studies. She has also supported many pharmaceutical companies in the development of HEOR planning and RWE generation plans. Ms. Guérin has conducted health care research across many therapeutic areas, including oncology, hematology, dermatology, gastroenterology, rheumatology, neurology, psychiatry, endocrinology, cardiology and circulatory diseases, and respiratory diseases. She publishes frequently and is the coauthor of over 100 research papers published in numerous peer-reviewed journals and presented at a variety of scientific conferences.
New Vice Presidents
Dr. Alford specializes in the application of microeconomics, econometrics, and statistical methods to complex litigation matters in the areas of health care, antitrust and competition, agriculture, and labor and employment. She has experience managing case teams and supporting experts through all phases of litigation, including fact and expert discovery, class certification, and liability and damages. Dr. Alford also has extensive experience in developing flexible damages models for real-time use in high-stakes negotiations. In health care matters, she has supported testifying experts and counsel on issues related to alleged kickbacks, off-label marketing, delayed generic entry, and the misappropriation of trade secrets. In antitrust and competition matters, Dr. Alford has evaluated market definition, market power, and competitive dynamics, and analyzed class certification, liability, and damages issues in cases involving allegations of price-fixing and monopolization. Dr. Alford has also conducted economic research across a variety of areas, including labor and employment, health care, and the effects of marijuana legalization.
Dr. Caminade specializes in the economic analysis of US and EU competition issues, as well as economic impact and policy studies. In numerous litigation projects, she has conducted conceptual, empirical, and documentary analyses; supervised case teams; assisted in the drafting of reports; and supported both internal and academic expert witnesses. Dr. Caminade’s experience spans all stages of the litigation process; includes Federal Trade Commission merger reviews and US Department of Justice antitrust investigations, as well as private litigation matters; and has covered multiple industries, with a focus on technology markets, as well as health care markets (including health care provider markets, insurance, and pharmaceuticals). Additionally, she has conducted or supervised dozens of economic impact studies and authored multiple white papers on matters pertaining to economic and industrial policy in technology markets. Dr. Caminade’s articles have appeared in publications such as the Journal of Competition Law & Economics and The Antitrust Source. She has taught competition economics at the undergraduate level in the economics department at Dartmouth College.
Dr. Cheng specializes in applying epidemiologic methods to assess the causal relationship of therapeutic agents with health and safety outcomes in observational studies. Her experience includes new drug application contingency studies and post-authorization safety studies for regulatory bodies; natural history studies; and real-world evidence development across multiple therapeutic areas. Dr. Cheng has particular expertise in applying advanced methodologies to address complex health care research challenges. She has used machine learning and other predictive modeling techniques, including latent class analysis to identify cost clusters in a disease patient population, group-based trajectory analysis to identify disease prognosis patterns, and rule-based approaches to diagnostic algorithms. Dr. Cheng has collected and utilized data from administrative insurance claims, large patient and physician surveys, clinical trials, electronic medical records, longitudinal observational studies, and site-based and panel-based medical chart reviews. She has conducted studies in more than 10 countries and published her research in numerous medical journals. Prior to joining Analysis Group, Dr. Cheng served as a research scientist at Columbia University and worked as a biostatistician in the Clinical Trials Network of the National Institute on Drug Abuse.
Dr. Cook uses economic theories, health care data, and statistical models to support health care policy decisions. She works on cost-effectiveness models, forecasting models, budget impact models, treatment comparisons, burden-of-illness analyses, chart reviews, literature reviews, global value dossiers, and commercial assessments in a range of therapeutic areas. Dr. Cook’s areas of expertise include measuring the clinical quality of health care providers, evaluating the impacts of health care innovations on utilization and health outcomes, comparing the clinical and cost effectiveness of treatment alternatives, and developing economic models of health interventions to guide decision making. She has experience developing cost-effectiveness models for gene therapy in hemophilia A and for a novel cancer screening tool; conducting multiple claims analyses; and supporting US product launches. Prior to joining Analysis Group, Dr. Cook was a health care policy researcher at Acumen LLC, where she directed federal contracts with the US Centers for Medicare & Medicaid Services (CMS) to implement components of the Affordable Care Act and support the Medicare program. She supported CMS rulemaking, authored reports to Congress, developed quality-of-care metrics, facilitated audits of Medicare Advantage plans, and assisted state Medicaid agencies, while gaining a deep understanding of Medicare and Medicaid eligibility requirements, benefit design, and reimbursement structure.
Dr. Desai specializes in health economics and outcomes research (HEOR), developing strategic solutions, and assisting with litigation matters in the health care sector. She has designed and managed numerous HEOR studies, including cost-of-illness analyses, comparative effectiveness analyses, adherence and persistence evaluations, patient/physician surveys, and pharmacoeconomic modeling. Her work spans several disease areas, including Alzheimer’s disease and related dementias; diabetes; and respiratory illnesses. Dr. Desai’s research has been presented at numerous conferences and published in peer-reviewed journals such as Diabetes Care, Alzheimer’s & Dementia, Health Affairs, and the Journal of Medical Economics, as well as in non-academic outlets such as STAT. She has served as an associate editor for the Journal of Alzheimer’s Disease. On the strategy side, Dr. Desai has developed formulary dossiers and presentation materials to assist clients with the commercialization of pharmaceutical products. In her litigation work, she has assisted in several cases in the health care sector involving patent disputes, antitrust issues, and False Claims Act issues. Prior to joining Analysis Group, Dr. Desai was a graduate teaching and research assistant at Virginia Commonwealth University.
Dr. Lu specializes in the application of microeconomics, econometrics, and statistical methods to complex litigation matters. She has conducted analyses of antitrust and competition issues across a range of industries, including health care and consumer products. In merger investigations, Dr. Lu has supported experts for the US Department of Justice and the Federal Trade Commission. She has also supported experts on issues related to intellectual property and commercial litigation in industries such as pharmaceuticals, biotechnology, and telecommunications. Dr. Lu’s research has been published in journals including the American Economic Journal: Applied Economics and the American Journal of Health Economics.
Ms. Milsark specializes in survey research and quantitative analysis in litigation, including data security and privacy, false advertising, and intellectual property matters. She has conducted qualitative and quantitative analyses in support of academic experts and provided consulting support to attorneys in matters across a variety of industries, including technology, media, retail, and consumer financial products. Ms. Milsark has managed case teams in several class action litigation matters involving violations of the Telephone Consumer Protection Act and assisted in evaluating violation claims, addressing class certification issues such as ascertainability and injury, and supporting experts in assessing whether dialer systems constitute Automatic Telephone Dialing Systems. She has supported consumer behavior experts studying consumer attention to and evaluation of information throughout the consumer purchase journey. Ms. Milsark has also provided support to experts in conducting and evaluating survey research studying consumer attention, interest, understanding, and purchase likelihood in the context of consumer products across industries.
Mr. Mitchell leads Analysis Group’s Office Administration and Operations team of more than 50 employees. He has direct responsibility for global facilities, office administration, security, emergency management, procurement, and executive support. In this role, Mr. Mitchell has enhanced daily administrative operations, streamlined processes, and reduced costs. He has played a critical role in developing and implementing the firm’s response to the COVID-19 pandemic. Prior to joining Analysis Group, Mr. Mitchell was associate vice president for campus and auxiliary services at Teachers College, Columbia University.
Ms. Offner specializes in the application of consumer behavior and marketing research methods to litigation matters and strategic business problems. Her experience encompasses issues related to intellectual property (IP), telecommunications, and commercial disputes and damages matters. She has supported academic affiliates in all phases of the litigation process, including preparation of expert reports, depositions, and trial testimony. Ms. Offner has extensive experience in the development, administration, and analysis of surveys in false advertising and IP litigation matters. She has also assisted clients in cases involving the alleged impact of a stigma on consumers’ valuations of properties, the potential for consumer confusion due to trademark infringement, the impact of advertisement claims on consumer purchase behavior, and competitive interactions between firms from the consumer perspective. In these and other litigation matters, she has supported leading marketing authorities in designing, implementing, and evaluating survey and other data-driven approaches.
Ms. Offner has also provided litigation support in a variety of telecommunications, regulated utilities, and securities matters. Her engagements have involved modeling the economic incentives of high-speed internet service providers to retain copyright-infringing subscribers, and evaluating the economic and financial feasibility of municipal takeovers of investor-owned water utilities in California. Ms. Offner also has experience estimating potential exposure across a wide variety of mortgage-backed securities lawsuits and mediations, and has submitted a declaration on this topic.
Mr. Pilon specializes in biostatistics and health economics and outcomes research. He has conducted and directed numerous studies and analyses for the investigation of topics such as clinical efficacy, cost of illness, cost effectiveness, resource utilization patterns, and treatment patterns in a wide range of therapeutic areas, including major depressive disorders, schizophrenia, oncology, inflammatory bowel diseases, dermatology, respiratory diseases, diabetes, and cardiovascular diseases.
Mr. Pilon has extensive experience performing retrospective insurance claims database analyses, retrospective electronic medical record studies, prospective survey studies, and clinical trial data analyses. He has presented his research at numerous international conferences, including meetings of the American Psychiatric Association and American Society of Clinical Oncology, and published articles in several peer-reviewed journals, including the Journal of Clinical Psychiatry, the Journal of Managed Care & Specialty Pharmacy, Advances in Therapy, Menopause, Clinical Therapeutics, Current Medical Research and Opinion, and Urologic Oncology.
Dr. Smith specializes in the application of microeconomics, statistics, and econometrics in the context of litigation and business disputes. He has served as an expert and conducted economic analyses in support of academic and industry experts in complex litigation matters involving antitrust, finance, accounting, class certification, and personal injury, and in contractual disputes. In antitrust engagements, he has investigated allegations of monopolization, price discrimination, exclusive dealing, and price-fixing. His finance experience includes matters involving securities fraud, loss causation, due diligence practices, fiduciary duty, and failure to disclose material information. Dr. Smith has served as an expert witness in breach of contract, labor dispute, personal injury, and price discrimination matters. He has worked closely with attorneys in all phases of litigation, including developing case strategy, presenting economic models, critiquing opposing experts’ analyses, developing trial demonstratives, and preparing expert witnesses. Dr. Smith has worked on behalf of the US Department of Justice and firms across a range of industries, including financial services, health care, manufacturing, media, payment card services, pharmaceuticals, private equity, and transportation. He is a contributor to the American Bar Association publication Proving Antitrust Damages. Prior to joining Analysis Group, he taught undergraduate economics at The University of Chicago, and worked in management consulting and investment banking. In his doctoral studies, Dr. Smith specialized in industrial organization and finance.
Dr. Song is an epidemiologist with expertise in biostatistics and clinical medicine, which he uses to address a wide array of analytical questions in health care. He has broad experience designing and implementing advanced and innovative real-world data analytic and economic modeling solutions for pharmaceutical clients. Dr. Song conducts research to evaluate and compare the clinical, economic, and humanistic impacts of diseases and treatments across a variety of therapeutic areas. He is experienced in disease areas including oncology, hematology, infectious disease and vaccines, dermatology, rheumatology, endocrinology, and ophthalmology. Dr. Song has provided cross-indication consulting for multiple blockbuster pharmaceutical products as well as novel pipeline agents. In his work, Dr. Song uses data from clinical trials, administrative claims, medical chart reviews, surveys, qualitative interviews, and medical literature. His research has covered many different study types, including disease epidemiology, burden of illness, disease treatment and management patterns, comparative effectiveness research, individualized medicine, systematic literature reviews, indirect treatment comparisons, cost-effectiveness analyses, budget impact analyses, analyses of patient-reported outcomes, and preference research such as discrete-choice experiments. Dr. Song’s work has been published in peer-reviewed journals and presented at international conferences on medical and health care research.
Dr. Trujillo specializes in applying financial, statistical, and economic analyses to complex business disputes across a wide variety of industries, including financial services, technology, automotive, telecommunications, health care, oil and gas, and entertainment. He has been involved in all phases of the litigation process, from review of pretrial discovery to expert report, deposition, and trial preparation; and he has testified as a damages expert in deposition and in arbitration on matters involving causation, breach of contract, and unfair competition. Dr. Trujillo’s intellectual property experience includes assessing reasonable royalties, price erosion, lost profits, and disgorgement damages for patent, trademark, and copyright infringement matters involving consumer and commercial products. He has also applied quantitative, statistical, and forensic techniques to address damages and class certification issues in commercial litigation matters involving asset misappropriation, medical and legal malpractice, taxes and accounting, and product liability, and in assisting government entities on public policy issues. Dr. Trujillo’s valuation experience includes privately held companies, trade secrets, and patent portfolios for public companies. Prior to joining Analysis Group, Dr. Trujillo worked as a chemical process engineer, and taught statistics as a course assistant at the MIT Sloan School of Management.
Dr. Zetenyi specializes in applying microeconomics, econometrics, and statistical methods to complex litigation and non-litigation matters in antitrust and competition, and in labor and employment. In antitrust and competition matters, Dr. Zetenyi has extensive experience across a variety of industries and market types, such as health care, airlines, agriculture, software, and newspapers, and two-sided digital platforms. He has evaluated market definition, market power, and competitive effects in cases involving allegations of monopolization and monopsonization, price-fixing, and other anticompetitive conduct. In labor and employment matters, Dr. Zetenyi has analyzed the platform business model of ride-sharing companies, and the potential impact of reclassification in cases involving allegations of driver misclassification. His non-litigation experience has included the evaluation of the efficacy of Australia’s tobacco plain packaging legislation.
Analysis Group Managing Principals and Principals
T. Christopher Borek
Maureen M. Chakraborty
Laurits R. Christensen
Pierre Y. Cremieux, President
Nicholas I. Crew
Bruce F. Deal
Mei Sheng Duh
Mark H. Egland
Brian S. Gorin
Paul E. Greenberg
Mark A. Gustafson
D. Lee Heavner
Paul J. Hibbard
John C. Jarosz
Jeffrey H. Kinrich
Rebecca Kirk Fair
R. Jeffrey Malinak
Justin N. McLean
David N. Mishol
Marnie A. Moore
Richard A. Mortimer
Carla S. Mulhern
Lisa B. Pinheiro
Martha S. Samuelson,
CEO and Chairman
David W. Sosa
Bruce E. Stangle, Co-founder
Richard M. Starfield
Bruce A. Strombom
Marc Van Audenrode
Robert L. Vigil
Alan G. White
Eric Q. Wu
A Leading Provider of Economic Analysis
Analysis Group is one of the largest international economics consulting firms, with more than 1,000 professionals across 14 offices in North America, Europe, and Asia. Since 1981, we have provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune Global 500 companies, and government agencies worldwide. Our internal experts, together with our network of affiliated experts from academia, industry, and government, offer our clients exceptional breadth and depth of expertise.